BIOLASE (BIOL) Diolase 10 Cleared by FDA for Use in Additional Markets
BIOLASE, Inc. (NASDAQ: BIOL) announced today that the U.S. Food and Drug Administration (FDA) has cleared the 940nm Diolase 10 diode soft tissue laser for use in 19 additional medical markets including: ear, nose and throat, oral surgery, arthroscopy, gastroenterology, general surgery, dermatology, plastic surgery, podiatry, GI/GU, gynecology, neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery, thoracic surgery, urology, dermatology, aesthetics, and vascular surgery. This FDA clearance includes over 80 different procedures.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EPIRUS Biopharma (EPRS) Commences BOW015 Phase 3 in RA
- Oasmia Pharma (OASM) Submitted MAA for Lead Cancer Product Apealea
- Insys Therapeutics (INSY) Enrolls First Patient in CBD Phase 2 as Infantile Spasms Treatment
Create E-mail Alert Related CategoriesFDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!